Skip to main content

Table 1 Characteristics of randomized controlled trials of ramosetron vs placebo in irritable bowel syndrome with diarrhea

From: Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials

Study Country Criteria for IBS Sample size
(ramosetron vs placebo)
Dose Treatment duration Follow-up duration Primary outcomes Secondary outcomes
Matsueda K 2008a [25] Japan Rome II 270 vs 269 5 μg 12 weeks 12 weeks Relief of overall IBS symptoms 1.Relief of abdominal discomfort/pain
2.Improvement in abnormal bowel habits
3.Assessment of IBS symptomsa
Matsueda K 2008b [26] Japan Rome II 103 vs 109 5 μg 12 weeks 12 weeks Relief of overall IBS symptoms 1.Relief of abdominal discomfort/pain
2.Improvement in abnormal bowel habits
3.Assessment of IBS symptomsa
Fukudo S 2014 [22] Japan Rome III 147 vs 149 5 μg 12 weeks 12 weeks Improvement in stool consistency 1.Relief of overall IBS symptoms
2.Relief of abdominal discomfort/pain
3.Improvement in abnormal bowel habits
4.Assessment of IBS symptomsa
5.IBS-QOL
Fukudo S 2015 [23] Japan Rome III 292 vs 284 2.5 μg 12 weeks 12 weeks 1.Relief of overall IBS symptoms
2.Improvement in stool consistency
1.Relief of abdominal discomfort/pain
2.Improvement in abnormal bowel habits
3.Assessment of IBS symptomsa
4.IBS-QOL
  1. IBS-QOL, irritable bowel syndrome-quality of life
  2. aAssessment of IBS symptoms included severity of abdominal discomfort and/or pain, stool form, stool frequency, urgency and feeling of incomplete bowel movement